LOTTE BIOLOGICS Signs Letter of Intent (LOI) for 

Strategic Collaboration with U.S.-Based Multinational Company that has also presence and operation in Japan and Taiwan

■ Signs LOI with U.S.-Based Global Group for Strategic Collaboration

■ Strengthens Synergy and Expands Cross-Border Opportunities

LOTTE BIOLOGICS (CEO James Park) announced that it has signed a Letter of Intent (LOI) for strategic business collaboration with a multinational biotechnology company headquartered in the United States. The partner’s innovative therapy, approved and launched in Japan ahead of other global markets, has shown strong clinical and commercial success. Several pipeline programs are also underway across multiple countries, including the United States and Japan.

Through this agreement, the two companies will jointly pursue a long-term partnership focused on collaborative framework in manufacturing of monoclonal antibodies and antibody-drug conjugates (ADCs). LOTTE BIOLOGICS views this LOI as the first step in building a trusted partnership with its counterpart, laying the foundation for structured cooperation and future joint initiatives. Building on this partnership, the company plans to further expand its CDMO business and strengthen brand recognition in Japan as well as the United States.

As part of the collaboration, LOTTE BIOLOGICS will provide manufacturing services from its Syracuse site in the United States. 

LOTTE BIOLOGICS stated that the signing of this LOI reflects recognition of its quality, manufacturing expertise, and geographic advantages. The companies plan to establish a stable and efficient communication framework while exploring opportunities for potential commercial-scale manufacturing.

The LOI was signed during BIO Japan 2025, where CEO James Park along with key members of LOTTE BIOLOGICS’ leadership actively engaged with stakeholders — holding discussions not only with major multinational pharmaceutical companies in Japan, but also with local mid-sized enterprises and emerging biotech firms.

A LOTTE BIOLOGICS spokesperson commented, “This agreement represents a meaningful first achievement with a partner that has a strong presence in Japan, built on our commitment to quality, transparency, and long-term collaboration,” adding, “We will continue to strengthen our global competitiveness and expand client partnerships through upcoming global events such as CPHI Worldwide and World ADC San Diego, further broadening our customer network.”